Gilead signs a US$4.9 billion acquisition deal with Forty Seven
By Nikita Chaurasia  Date: 2020-03-03

Gilead signs a US$4.9 billion acquisition deal with Forty Seven

The deal would improve Gilead’s portfolio in Oncology and would allow the firm to conduct new First-in-Class oncology programs.

Gilead Sciences Inc., a U.S. based biotechnology company, has recently announced that it has inked a definitive agreement to acquire immuno-oncology company, Forty Seven Inc. for $4.9 billion. Reportedly, the transaction valued each share at $95.50 and was unanimously approved by the Boards of Directors of both the companies.

Reports cite that this acquisition deal could close by Q2 of 2020, subject to customary closing conditions and regulatory approvals. With this acquisition, Gilead’s immuno-oncology R&D portfolio would greatly benefit from the addition of Forty Seven’s lead drug candidate, magrolimab. 

Speaking on the move, Daniel O’Day, Chief Executive Officer and Chairman, Gilead Sciences, said that this deal would enhance Gilead’s presence in immuno-oncology and strengthen its portfolio as well as its clinical pipeline. Moreover, magrolimab would benefit its work in hematology, adding up a non-cell therapy initiative that accompanies Kite’s lineup of cell therapies developed for hematological cancers. 

Additionally, the biotech is looking forward to working with Forty Seven’s highly experienced team as it develops new treatments for some of the most complicated cancer forms, adds O’Day

Prior to this news, Gilead Sciences had made headlines when it revealed that it has appointed Sandra Horning, MD, in its Board of Directors. Reportedly, Dr. Horning had previously served as the Global Head of Product Development and Chief Medical Officer for Roche. 

Commenting on which, O’Day said that the company is delighted to welcome Sandra Horning in its Board of Directors and is looking forward to sharing her immense experience and vast industry expertise in drug development across numerous therapeutic sectors.

Additionally, Dr. Horning possesses the perspective of a leading physician who has invested over two decades in cancer treatment, that would come in handy while making strategic decisions for the company.

Source Credit: https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Nokia, Greener Acres partner to boost smart city development in Canada
Nokia, Greener Acres partner to boost smart city development in Canada
By Nikita Chaurasia

According to reliable sources, Finnish multinational telecommunication, consumer electronics and information technology company Nokia Corp. has reportedly signed an agreement with Greener Acres Canada Inc. to collectively develop and upgrade the util...

OneOncology launches OneR to accelerate clinical research programs
OneOncology launches OneR to accelerate clinical research programs
By Nikita Chaurasia

In recent developments, Tennessee-based oncology medical service provider OneOncology Inc., has reportedly announced the establishment of a newly formed subsidiary named OneR (OneOncology Research Network). Sources close to the matter claimed that O...

Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
By Nikita Chaurasia

According to reliable sources, U.S.-based critical infrastructure service provider of cannabis industry, Helix Technologies Inc. has reportedly announced a strategic merger with Medical Outcomes Research Analytics LLC (MOR Analytics) to become wholly...

German software firm Celonis launches the market’s first EMS
German software firm Celonis launches the market’s first EMS
By Nikita Chaurasia

Celonis, a German leader in AI-enhanced Process Excellence and Process Mining, has reportedly launched the first EMS (Execution Management System) of the industry. The company has specifically developed the EMS to remove system complexity, which is t...

Informatica adds advanced capabilities to enterprise cloud platform
Informatica adds advanced capabilities to enterprise cloud platform
By Nikita Chaurasia

Informatica, a leading US based enterprise cloud data management firm, has reportedly rolled out new, enhanced capabilities that are designed to help its clients become cloud-native, cloud-first in the COVID-19 pandemic. IDC (International Data Corpo...